Babbage: Is ketamine the next antidepressant?

In America and Europe, a growing number of clinics are offering ketamine to treat depression. The anaesthetic—also used illegally as a party drug—can provide rapid relief from the condition where traditional treatments, such as antidepressant drugs, have failed. We investigate how the therapy works, and ask what role it will play in the future of mental-health care. And, as ketamine treatments spread, is enough known about the drug’s long-term safety? Alok Jha hosts with Natasha Loder, The Economist’s health policy editor.For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience. Hosted on Acast. See acast.com/privacy for more information.

Om Podcasten

Babbage is our weekly podcast on science and technology, named after Charles Babbage—a 19th-century polymath and grandfather of computing. Host Alok Jha talks to our correspondents about the innovations, discoveries and gadgetry shaping the world. Published every Wednesday.If you’re already a subscriber to The Economist, you’ll have full access to all our shows as part of your subscription.For more information about Economist Podcasts+, including how to get access, please visit our FAQs page here https://myaccount.economist.com/s/article/What-is-Economist-Podcasts Hosted on Acast. See acast.com/privacy for more information.